Spondyloarthropathies News

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.

TNF inhibitors have similar rates of adverse events and treatment response in ankylosing spondylitis regardless of whether the disease developed early or late in life, according to data published in Scientific Reports.

ORLANDO, Fla. — Understanding the nuances of spondyloarthropathy diagnostic criteria can help prevent “debilitating” consequences, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

A long-term, supervised exercise program for patients with axial spondyloarthritis and severe functional limitations improved functional disability and physical quality of life vs. usual care, according to data published in Rheumatology.

The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.

Patients with rheumatic diseases demonstrate a high reliance on opioids around the time of diagnosis, and significant numbers of patients were not on appropriate treatment in the year afterward, according to data in Clinical Rheumatology.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The effectiveness of TNF inhibitors for axial spondyloarthritis varies significantly between men and women based on BASDAI score, but not ASDAS, according to data published in Arthritis Research & Therapy.